RESUMEN
PURPOSE: Euterpe oleracea Mart. (açaí) seed extract (ASE), through its anti-hypertensive, antioxidant and anti-inflammatory properties, may be useful to treat or prevent human diseases. Several evidences suggest that oxidative stress and inflammation contribute to the pathogenesis of diabetic nephropathy; therefore, we tested the hypothesis that ASE (200 mg/kg-1day-1) prevents diabetes and hypertension-related oxidative stress and inflammation, attenuating renal injury. METHODS: Male rats with streptozotocin (STZ)-induced diabetes (D), and spontaneously hypertensive rats with STZ-induced diabetes (DH) were treated daily with tap water or ASE (D + ASE and DH + ASE, respectively) for 45 days. The control (C) and hypertensive (H) animals received water. RESULTS: The elevated serum levels of urea and creatinine in D and DH, and increased albumin excretion in HD were reduced by ASE. Total glomeruli number in D and DH, were increased by ASE that also reduced renal fibrosis in both groups by decreasing collagen IV and TGF-ß1 expression. ASE improved biomarkers of renal filtration barrier (podocin and nephrin) in D and DH groups and prevented the increased expression of caspase-3, IL-6, TNF-α and MCP-1 in both groups. ASE reduced oxidative damage markers (TBARS, carbonyl levels and 8-isoprostane) in D and DH associated with a decrease in Nox 4 and p47 subunit expression and increase in antioxidant enzyme activity in both groups (SOD, catalase and GPx). CONCLUSION: ASE substantially reduced renal injury and prevented renal dysfunction by reducing inflammation, oxidative stress and improving the renal filtration barrier, providing a nutritional resource for prevention of diabetic and hypertensive-related nephropathy.
Asunto(s)
Antioxidantes/uso terapéutico , Nefropatías Diabéticas/prevención & control , Suplementos Dietéticos , Euterpe/química , Extractos Vegetales/uso terapéutico , Insuficiencia Renal/prevención & control , Semillas/química , Animales , Antiinflamatorios no Esteroideos/uso terapéutico , Antihipertensivos/uso terapéutico , Apoptosis , Biomarcadores/sangre , Biomarcadores/metabolismo , Biomarcadores/orina , Diabetes Mellitus Experimental/complicaciones , Diabetes Mellitus Experimental/dietoterapia , Diabetes Mellitus Experimental/inmunología , Nefropatías Diabéticas/complicaciones , Nefropatías Diabéticas/metabolismo , Nefropatías Diabéticas/patología , Fibrosis , Barrera de Filtración Glomerular/inmunología , Barrera de Filtración Glomerular/metabolismo , Barrera de Filtración Glomerular/patología , Barrera de Filtración Glomerular/fisiopatología , Hipertensión/complicaciones , Hipertensión/dietoterapia , Hipertensión/inmunología , Hipertensión/fisiopatología , Mediadores de Inflamación/sangre , Mediadores de Inflamación/metabolismo , Riñón/inmunología , Riñón/metabolismo , Riñón/patología , Riñón/fisiopatología , Estrés Oxidativo , Ratas Endogámicas SHR , Insuficiencia Renal/complicaciones , Insuficiencia Renal/etiología , Insuficiencia Renal/metabolismoRESUMEN
On the basis of observational studies, the most common cause of nephrotic syndrome in school-aged children is minimal change disease. On the basis of research evidence and consensus, corticosteroids are considered first-line therapy for treatment of nephrotic syndrome. On the basis of consensus, prednisone therapy should be initiated at doses of 60 mg/m2 per day (2 mg/kg per day) administered for 4 to 6 weeks, followed by 40 mg/m2 per dose (1.5 mg/kg) every other day for at least 6 to 8 weeks. On the basis of consensus and expert opinion, it is important to recognize and manage the complications that can arise in patients with nephrotic syndrome, such as dyslipidemia, infection, and thrombosis. On the basis of research evidence, consensus, and expert opinion, several alternative therapies have been observed to have variable efficacy in children with both corticosteroid-dependent and corticosteroid-resistant nephrotic syndrome, although caution must be exercised in the administration of these corticosteroid-sparing medications secondary to toxic adverse effects. On the basis of observational studies, the course of nephrotic syndrome in most patients is that of relapse and remission.
Asunto(s)
Glucocorticoides/administración & dosificación , Síndrome Nefrótico/diagnóstico , Síndrome Nefrótico/tratamiento farmacológico , Prednisona/administración & dosificación , Corticoesteroides/uso terapéutico , Niño , Preescolar , Manejo de la Enfermedad , Femenino , Barrera de Filtración Glomerular/fisiopatología , Humanos , Lactante , Riñón/fisiopatología , Masculino , Síndrome Nefrótico/etiología , Pediatría/educaciónRESUMEN
Glomerular endothelial surface layer (ESL) may play a role in the mechanisms of albuminuria in diabetic nephropathy, which lack evidence in vivo. The effects of high glucose on the passage of albumin across the glomerular ESL were analysed in streptozotocin-induced diabetic Sprague-Dawley rats for 4 weeks. Albuminuria and glomerular mesangial matrix were significantly increased in diabetic rats. The passage of albumin across the ESL, as measured by albumin-colloid gold particle density in the glomerular basement membrane (GBM), was increased significantly in diabetic rats. The thickness of the glomerular ESL, examined indirectly by infusing Intralipid into vessels using an electron microscope, was significantly decreased and the GBM exhibited little change in diabetic rats. In summary, the glomerular ESL may play a role in the pathogenesis of albuminuria in rats with early-stage diabetes.